Reducing risk in lentiviral-based gene therapy with innovative solutions:
A review for leveraging historical technologies in new ways
AUTHOR: Farzin Farzaneh Ph.D., CSO; Nicholas Ostrout Ph.D., VP Corporate Development & Strategy, Glenda Dickson Ph.D., Senior Principal Scientist, Innovation, and David Darling Ph.D., Senior Principal Scientist, Innovation, ViroCell Biologics
ViroCell Biologics London
12-18 Theobalds Road
London WC1X 8SL, UK
ViroCell Biologics New York
25 East 86th Street, Suite 3D
New York, NY 10028, USA